UK up­start rais­es $100M in bid to dig­i­tize and stan­dard­ize cell and gene ther­a­py man­u­fac­tur­ing

There’s a gi­ant need for cell and gene ther­a­py man­u­fac­tur­ing op­tions go­ing for­ward, as com­pa­nies move to in­vest mas­sive­ly in­to that space. Ori Biotech is the lat­est, as the UK-based biotech an­nounced it has se­cured more than $100 mil­lion in its over­sub­scribed Se­ries B fund­ing round Tues­day.

No­valis Life­Sciences led the round. The Boston-based com­pa­ny is led by chair­man Mar­i­jn Dekkers and part­ner Paul Meis­ter, who built Ther­mo Fish­er Sci­en­tif­ic. Dekkers went on to be­come the CEO of Bay­er, and is cur­rent­ly al­so the chair­man at Gink­go Bioworks.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER